172 related articles for article (PubMed ID: 25286754)
1. Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis.
Zhai JH; Gu WC; Xu XL; Wu J; Hu XJ; Hou KZ
Tumour Biol; 2015 Feb; 36(2):701-9. PubMed ID: 25286754
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
Zhong C; Wu JD; Fang MM; Pu LY
Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
[TBL] [Abstract][Full Text] [Related]
3. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
4. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X
Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004
[TBL] [Abstract][Full Text] [Related]
8. Abnormal FHIT protein expression may be correlated with poor prognosis in gastric cancer: a meta-analysis.
Wang HL; Zhou PY; Liu P; Zhang Y
Tumour Biol; 2014 Jul; 35(7):6815-21. PubMed ID: 24729090
[TBL] [Abstract][Full Text] [Related]
9. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
[TBL] [Abstract][Full Text] [Related]
10. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
12. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
13. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
14. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases.
Mehra N; Penning M; Maas J; Beerepoot LV; van Daal N; van Gils CH; Giles RH; Voest EE
Clin Cancer Res; 2006 Aug; 12(16):4859-66. PubMed ID: 16914572
[TBL] [Abstract][Full Text] [Related]
15. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Eto S; Yoshikawa K; Shimada M; Higashijima J; Tokunaga T; Nakao T; Nishi M; Takasu C; Sato H; Kurita N
Anticancer Res; 2015 Apr; 35(4):2071-6. PubMed ID: 25862862
[TBL] [Abstract][Full Text] [Related]
16. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.
Chen S; Song X; Chen Z; Li X; Li M; Liu H; Li J
PLoS One; 2013; 8(2):e56380. PubMed ID: 23409180
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD133 in acute leukemia.
Tolba FM; Foda ME; Kamal HM; Elshabrawy DA
Med Oncol; 2013 Jun; 30(2):527. PubMed ID: 23532815
[TBL] [Abstract][Full Text] [Related]
18. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
19. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
20. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies.
Wang HL; Zhou PY; Zhang Y; Liu P
Cancer Biother Radiopharm; 2014 May; 29(4):166-72. PubMed ID: 24784911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
